Content area

|
|

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Kutant melanom. (Foto: Pia Sjøgren).
Forfatter(e)
Louise Elkjær Fløe1, Inge Marie Svane2, Lars Bastholt3 & Henrik Schmidt1 1) Onkologisk Afdeling, Aarhus Universitetshospital 2) Center for Cancer Immunterapi, Herlev Hospital 3) Onkologisk Afdeling, Odense Universitetshospital Ugeskr Læger 2016;178:V01160070
Reference: 
Ugeskr Læger 2016;178:V01160070
Blad nummer: 
Sidetal: 
2-5
Immune checkpoint antibodies increase survival in patients with metastatic melanoma
The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Annette Randløv | 25/05
4 kommentarer
af Andreas Gothardt Lundh | 21/05
1 Kommentar
af Søren Dalsgaard | 20/05
1 Kommentar
af Anette Bygum | 19/05
10 kommentarer
af Hans-Iver G. F.-D Kley | 18/05
1 Kommentar
af Per Bonding | 17/05
1 Kommentar